Phase II study of interferon-alpha and doxycycline for advanced renal cell carcinoma

Investigational New Drugs

Volumn 24, Issue 3, 2006, Pages 255-260

  Huie, Michael ^a   Oettel, Kurt ^a   Van Ummersen, Lynn ^a   Kyung, Mann Kim ^a   Zhang, Yulin ^a   Staab, Mary Jane ^a   Horvath, Dottie ^a   Marnocha, Rebecca ^a   Douglas, Jeff ^a   Drezen, Amy ^a   Alberti, Dona ^a   Wilding, George ^a  

^a UNIVERSITY OF WISCONSIN   (United States)

Author keywords

Angiogenesis; Interferon; Phase II trial; Renal cancer; VEGF

Indexed keywords

ALPHA INTERFERON; DOXYCYCLINE; VASCULOTROPIN;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG DOSE REDUCTION; GASTROINTESTINAL TOXICITY; HUMAN; KIDNEY CARCINOMA; LIFE EXPECTANCY; METASTASIS; NEPHRECTOMY; OUTCOMES RESEARCH; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL;

ADULT; AGED; ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, RENAL CELL; DOXYCYCLINE; HUMANS; INTERFERON-ALPHA; KIDNEY NEOPLASMS; MIDDLE AGED; NAUSEA; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VOMITING; WEIGHT LOSS;

EID: 33646574286     PISSN: 01676997     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10637-005-3903-z     Document Type: Article

References (26)

1. Ahmedin J, Thomas A, Taylor M, Thun M: Cancer Statistics 2002. CA Cancer J Clin 52: 23-47, 2002
2. Motzer RJ, Bander NH, Nanus DM: Renal-Cell Carcinoma. N Engl J Med 335: 865-75, 1996
3. Eckhardt SG: Angiogenesis inhibitors as cancer therapy. Hospital Practice Jan 15, 1999
4. Slaton JW, Inoue K, Perotte P, El-Naggar AK, Swanson DA, Fidler H, Dinney CPN: Expression levels of genes that regulate metastases and angiogenesis correlate with advanced pathological stage of renal cell carcinoma. Am J Pathol 158: 735-743, 2001
5. Sasamura H, Takahashe A, Miyao N, Masumori N, Kitamura H, Itoh N, Tsukamoto T: Inhibitory expression of angiogenic factors by antiangiogenic agents in renal cell carcinoma. BJU Int 86: 768-773, 2002
6. Lokeshwar BL: MMP inhibition in prostate cancer. Ann NY Acad Sci 878: 271-289, 1999
7. Kelly K: New chemotherapy. Chest 117(4): 156S-162S, 2000
8. Gu Y, Lee HM, Roemer EJ, Musacchia L, Golub LM, Simon SR: Inhibition of tumor cell invasiveness by chemically modified tetracyclines. Curr Med Chem 8(3): 261-270, 2001
9. Fife RS, Sledge GW, Roth BJ, Proctor C: Effects of doxycycline on human prostate cancer cells in vitro. Cancer Letters 127: 37-41, 1998
10. Fife RS, Sledge GW: Effects of doxycycline on in vitro growth, migration, and gelatinase activity of breast carcinoma cells. J Lab Clin Med 125: 407-411, 1995
11. Lukkonen A, Sorsa T, Salo T, Tervahartiala T, Koivunen E, Golub L, Simon S, Stenman UH: Down-regulation of trypsinogen-2 expression by chemicallymodified tetracyclines: association with reduced cancer cell migration. Int J Cancer 86(4): 577-581, 2000
12. Stebbing J, Gore M: The current status of interferon-(alpha) treatment in advanced renal cancer. BJU int 87(7): 599-601, 2001
13. Negrier S, Escudier B, Lasset C, Douillard JY, Savary J, Chevreau C, Ravaud A, Mercatello A, Peny J, Mousseau M, Philip T. Tursz T: Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. N Engl J of Med 338(18): 1272-1278, 1998
14. Stadler WM, Kuzel T, Shapiro C Sosman J, Clark J, Vogelzang NJ: Multi-institutional study of the angiogenesis inhibitor TNP-470 in metastatic renal cell carcinoma. J Clin Oncol 17(8): 2541-2545, 1999
15. Motzer RJ, Berg W, Ginsberg M, Russo P, Vuky J, Yu R, Bacik J, Mozumdar M: Phase II trial of thalidomide for patients with advanced renal cell carcinoma. J Clin Oncol 20(1): 302-306, 2002
16. Batist G, Patenaude F, Champagne P, Croteau D, Levinton C, Hariton C, Escudier B, Dupont E: Neovastat (AE-941) in refractory renal cell carcinoma patients: report of a phase II trial with two dose levels. Ann Oncol. 13(8): 1259-1263, 2002
17. Kuenen BC, Tabernero J, Baselga J, Cavalli F, Pfanner E, Conte PF, Seeber S, Madhusudan S, Deplanque G, Huisman H, Scigalla P, Hoekman K, Harris AL: Efficacy and toxicity of the angiogenesis inhibitor SU5416 as a single agent in patients with advanced renal cell carcinoma, melanoma, and soft tissue sarcoma. Clin Cancer Res 9(5): 1648-1655, 2003
18. Lara PN Jr, Quinn DI, Margolin K, Meyers FJ, Longmate J, Frankel P, Mack PC, Turrell C, Valk P, Rao J, Buckley P, Wun T, Gosselin R, Galvin I, Gumerlock PH, Lenz HJ, Doroshow JH, Gandara DR: SU5416 plus interferon alpha in advanced renal cell carcinoma: A phase II California Cancer Consortium Study with biological and imaging correlates of angiogenesis inhibition. Clin Cancer Res 9(13): 4772-4781, 2003
19. Hernberg M, Virkkunen P, Bono P, Ahtinen H, Maenpaa H, Joensuu H: Interferon alfa-2b three times daily and thalidomide in the treatment of metastatic renal cell carcinoma. J Clin Oncol 21(20): 3770-3776, 2003
20. Kuenen BC, Levi M, Meijers JC, Kakkar AK, van Hinsbergh VW. Kostense PJ, Pinedo HM, Hoekman K: Analysis of coagulation cascade and endothelial cell activation during inhibition of vascular endothelial growth factor/vascular endothelial growth factor receptor pathway in cancer patients. Arteriosclerosis. Thrombosis & Vascular Biology 22(9): 1500-1505, 2002
21. Motzer RJ, Rini BI, Michaelson M, Redman BG, Hudes GR, Wilding G, Bukowski DJ, George ST, Kim C, Baum M: Phase 2 trials of SU11248 show antitumor activity in second-line therapy for patients with metastatic renal cell carcinoma (RCC). ASCO Proc. Abstract 4508, 2005
22. Rini B, Rixi R, Bukowski MD, Michaelson G, Wilding G, Hudes O, Bolte H, Steinfeldt S, Reich D, Motzer R: AG-013736, a multi-target tyrosine kinase receptor inhibitor, demonstrates anti-tumor activity in a Phase 2 study of cytokine-refractory, metastatic renal cell cancer (RCC). ASCO Proc. Abstract 4509, 2005
23. Escudier B, Szczylik C, Eisen T, Stadler WM, Schwartz B, Shan M, Bukowski RM: Randomized Phase III trial of the Raf kinase and VEGFR inhibitor sorafenib (BAY 43-9006) in patients with advanced renal cell carcinoma (RCC). ASCO Proc. Abstract LB4510, 2005
24. Gordon MS, Battiato LA, Jones D, Roth BJ, Harrison-Mann B, Fife R, Collins M, Sledge GW: A phase I trial of doxycycline in patients with cancer. ASCO Proc Abstract 794, 1997
25. Liang KY, Zeger SL: Longitudinal data analysis using generalized linear models. Biometrika: 13-22, 1986
26. Motzer RJ, Mazumdar M, Bacik J, Berg W, Amsterdam A, Ferrara J: Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol 17(8): 2530-2540, 1999